Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria
Colin K. Skepper,Duncan Armstrong,Carl J. Balibar,Daniel Bauer,Cornelia Bellamacina,Bret M. Benton,Dirksen Bussiere,Gianfranco De Pascale,Javier De Vicente,Charles R. Dean,Bhavesh Dhumale,L. Mark Fisher,John Fuller,Mangesh Fulsunder,Lauren M. Holder,Cheng Hu,Bhavin Kantariya,Guillaume Lapointe,Jennifer A. Leeds,Xiaolin Li,Peichao Lu,Anatoli Lvov,Sylvia Ma,Shravanthi Madhavan,Swapnil Malekar,David McKenney,Wosenu Mergo,Louis Metzger,Heinz E. Moser,Daniel Mutnick,Jonas Noeske,Colin Osborne,Ashish Patel,Darshit Patel,Tushar Patel,Krunal Prajapati,Katherine R. Prosen,Folkert Reck,Daryl L. Richie,Alice Rico,Mark R. Sanderson,Shailesh Satasia,William S. Sawyer,Jogitha Selvarajah,Nirav Shah,Kartik Shanghavi,Wei Shu,Katherine V. Thompson,Martin Traebert,Anand Vala,Lakhan Vala,Dennis A. Veselkov,Jason Vo,Michael Wang,Marcella Widya,Sarah L. Williams,Yongjin Xu,Qin Yue,Richard Zang,Bo Zhou,Alexey Rivkin
DOI: https://doi.org/10.1021/acs.jmedchem.0c00347
IF: 8.039
2020-07-07
Journal of Medicinal Chemistry
Abstract:Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven largely by target-based mutations in the GyrA/ParC quinolone resistance determining region, have eroded the utility and threaten the future use of this vital class of antibiotics. Herein we describe the discovery and optimization of a series of 4-(aminomethyl)quinolin-2(1<i>H</i>)-ones, exemplified by <b>34</b>, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against ciprofloxacin-resistant Gram-negative pathogens. X-ray crystallography reveals that <b>34</b> occupies the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form significant contacts with residues in the quinolone resistance determining region.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00347?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00347</a>.Crystallographic data table for the structure of <i>K. pneumoniae</i> topoisomerase IV bound to compound <b>34</b>; unbiased electron-density difference map (<i>F</i><sub>obs</sub> – <i>F</i><sub>calc</sub>) for <b>34</b> bound to <i>K. pneumoniae</i> topoisomerase IV; interaction diagram of compound <b>34</b> bound to topoisomerase IV from <i>K. pneumoniae</i>; plot of CFU/thigh determined for each dose of compound <b>34</b> in the neutropenic murine thigh infection model; SEC chromatograms showing separation of supercoiled and relaxed DNA and detection of decatenated kDNA; LC/MS traces of all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_002.csv">CSV</a>)This article has not yet been cited by other publications.
chemistry, medicinal